{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-025688","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2025-08-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.726519+00:00","generated_at":"2026-05-17T09:48:55.874880+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Telomir reports in vitro data: Telomir-1 inhibits UTX and modestly targets Tankyrases","bullets":["Telomir-1 potently inhibits UTX (KDM6A), a histone demethylase linked to cancer, aging, neurodegeneration.","Low-level inhibition of Tankyrases (PARP5A/B) may disrupt Wnt/β-catenin pathway without telomere shortening risks.","Selectivity vs GCN5L2 suggests cleaner safety margin vs other epigenetic drugs.","Prior in vivo data showed reactivation of tumor suppressors STAT1/TMS1 and telomere elongation."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-025688","json":"https://secwatch.observer/filing/0001641172-25-025688.json","markdown":"https://secwatch.observer/filing/0001641172-25-025688.md","text":"https://secwatch.observer/filing/0001641172-25-025688.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000164117225025688/0001641172-25-025688-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000164117225025688/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:48:55.874880+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}